000163453 001__ 163453
000163453 005__ 20230915090520.0
000163453 0247_ $$2doi$$a10.1186/s40478-022-01327-6
000163453 0247_ $$2pmid$$apmid:35209932
000163453 0247_ $$2pmc$$apmc:PMC8867857
000163453 0247_ $$2altmetric$$aaltmetric:123730747
000163453 037__ $$aDZNE-2022-00213
000163453 041__ $$aEnglish
000163453 082__ $$a610
000163453 1001_ $$0P:(DE-2719)2812190$$aLohmann, Stephanie$$b0$$eFirst author$$udzne
000163453 245__ $$aIschemic stroke causes Parkinson's disease-like pathology and symptoms in transgenic mice overexpressing alpha-synuclein.
000163453 260__ $$aLondon$$bBiomed Central$$c2022
000163453 3367_ $$2DRIVER$$aarticle
000163453 3367_ $$2DataCite$$aOutput Types/Journal article
000163453 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1654865502_23357
000163453 3367_ $$2BibTeX$$aARTICLE
000163453 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000163453 3367_ $$00$$2EndNote$$aJournal Article
000163453 520__ $$aThe etiology of Parkinson's disease is poorly understood and is most commonly associated with advancing age, genetic predisposition, or environmental toxins. Epidemiological findings suggest that patients have a higher risk of developing Parkinson's disease after ischemic stroke, but this potential causality lacks mechanistic evidence. We investigated the long-term effects of ischemic stroke on pathogenesis in hemizygous TgM83 mice, which express human α-synuclein with the familial A53T mutation without developing any neuropathology or signs of neurologic disease for more than 600 days. We induced transient focal ischemia by middle cerebral artery occlusion in 2-month-old TgM83+/- mice and monitored their behavior and health status for up to 360 days post surgery. Groups of mice were sacrificed at 14, 30, 90, 180, and 360 days after surgery for neuropathological analysis of their brains. Motor deficits first appeared 6 months after focal ischemia and worsened until 12 months afterward. Immunohistochemical analysis revealed ischemia-induced neuronal loss in the infarct region and astrogliosis and microgliosis indicative of an inflammatory response, which was most pronounced at 14 days post surgery. Infarct volume and inflammation gradually decreased in size and severity until 180 days post surgery. Surprisingly, neuronal loss and inflammation were increased again by 360 days post surgery. These changes were accompanied by a continuous increase in α-synuclein aggregation, its neuronal deposition, and a late loss of dopaminergic neurons in the substantia nigra, which we detected at 360 days post surgery. Control animals that underwent sham surgery without middle cerebral artery occlusion showed no signs of disease or neuropathology. Our results establish a mechanistic link between ischemic stroke and Parkinson's disease and provide an animal model for studying possible interventions.
000163453 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000163453 536__ $$0G:(DE-HGF)POF4-351$$a351 - Brain Function (POF4-351)$$cPOF4-351$$fPOF IV$$x1
000163453 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000163453 650_7 $$2Other$$aAlpha-synuclein
000163453 650_7 $$2Other$$aIschemia
000163453 650_7 $$2Other$$aIschemic stroke
000163453 650_7 $$2Other$$aParkinson’s disease
000163453 650_7 $$2Other$$aStroke
000163453 650_7 $$2Other$$aSynucleinopathy
000163453 650_2 $$2MeSH$$aAnimals
000163453 650_2 $$2MeSH$$aDisease Models, Animal
000163453 650_2 $$2MeSH$$aDopaminergic Neurons: pathology
000163453 650_2 $$2MeSH$$aHumans
000163453 650_2 $$2MeSH$$aInfarction, Middle Cerebral Artery: complications
000163453 650_2 $$2MeSH$$aInflammation: complications
000163453 650_2 $$2MeSH$$aIschemic Stroke
000163453 650_2 $$2MeSH$$aMice
000163453 650_2 $$2MeSH$$aMice, Transgenic
000163453 650_2 $$2MeSH$$aParkinson Disease: complications
000163453 650_2 $$2MeSH$$aParkinson Disease: genetics
000163453 650_2 $$2MeSH$$aParkinson Disease: pathology
000163453 650_2 $$2MeSH$$aalpha-Synuclein: genetics
000163453 7001_ $$0P:(DE-2719)2812381$$aGrigoletto, Jessica$$b1$$udzne
000163453 7001_ $$0P:(DE-2719)2810557$$aBernis, Maria Eugenia$$b2$$udzne
000163453 7001_ $$0P:(DE-2719)2811818$$aPesch, Verena$$b3$$udzne
000163453 7001_ $$aMa, Liang$$b4
000163453 7001_ $$aReithofer, Sara$$b5
000163453 7001_ $$0P:(DE-2719)2810376$$aTamgüney, Gültekin$$b6$$udzne
000163453 773__ $$0PERI:(DE-600)2715589-4$$a10.1186/s40478-022-01327-6$$gVol. 10, no. 1, p. 26$$n1$$p26$$tActa Neuropathologica Communications$$v10$$x2051-5960$$y2022
000163453 8564_ $$uhttps://pub.dzne.de/record/163453/files/DZNE-2022-00213.pdf$$yOpenAccess
000163453 8564_ $$uhttps://pub.dzne.de/record/163453/files/DZNE-2022-00213.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000163453 909CO $$ooai:pub.dzne.de:163453$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000163453 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812190$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000163453 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812381$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000163453 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810557$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000163453 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2811818$$aExternal Institute$$b3$$kExtern
000163453 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2810376$$aExternal Institute$$b6$$kExtern
000163453 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000163453 9131_ $$0G:(DE-HGF)POF4-351$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vBrain Function$$x1
000163453 9141_ $$y2022
000163453 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-01-28
000163453 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-28
000163453 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-28
000163453 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-28
000163453 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-01-28
000163453 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000163453 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-01-28
000163453 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bACTA NEUROPATHOL COM : 2021$$d2022-11-09
000163453 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-09
000163453 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-09
000163453 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-02-14T16:20:11Z
000163453 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-02-14T16:20:11Z
000163453 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-02-14T16:20:11Z
000163453 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-09
000163453 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-09
000163453 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-09
000163453 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-09
000163453 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-09
000163453 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bACTA NEUROPATHOL COM : 2021$$d2022-11-09
000163453 9201_ $$0I:(DE-2719)1013004$$kAG Vorberg$$lPrion Cell Biology$$x0
000163453 9201_ $$0I:(DE-2719)1013022$$kAG Tamgüney 2$$lPrion and prion-like diseases$$x1
000163453 9201_ $$0I:(DE-2719)1013033$$kAG Capasso$$lImmune Regulation$$x2
000163453 980__ $$ajournal
000163453 980__ $$aVDB
000163453 980__ $$aUNRESTRICTED
000163453 980__ $$aI:(DE-2719)1013004
000163453 980__ $$aI:(DE-2719)1013022
000163453 980__ $$aI:(DE-2719)1013033
000163453 9801_ $$aFullTexts